Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-Clear Cell Renal Cell Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05620134
What this trial is testing

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Who this might be right for
CancerTumor, SolidAdvanced Solid Tumor+19 more
Salubris Biotherapeutics Inc 263
Testing effectiveness (Phase 2)Study completedNCT05597839
What this trial is testing

Study of DF9001 in Patients With Advanced Solid Tumors

Who this might be right for
Solid Tumor, Adult
Dragonfly Therapeutics 24
Early research (Phase 1)Study completedNCT00827177
What this trial is testing

Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 87
Not applicableStudy completedNCT05650164
What this trial is testing

Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2)

Who this might be right for
Renal Cell Carcinoma
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany 171
Testing effectiveness (Phase 2)Study completedNCT01265368
What this trial is testing

A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcinoma (ASET)

Who this might be right for
Stage IV Renal Cell Cancer
Mologen AG 19
Testing effectiveness (Phase 2)Study completedNCT03511391
What this trial is testing

CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors

Who this might be right for
Urothelial CarcinomaMelanomaRenal Cell Carcinoma+2 more
University Hospital, Ghent 99
Testing effectiveness (Phase 2)Study completedNCT01108445
What this trial is testing

Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma

Who this might be right for
Advanced Non-clear Cell Renal Cell Carcinoma
Duke University 131
Early research (Phase 1)Active Not RecruitingNCT05544929
What this trial is testing

Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

Who this might be right for
Carcinoma, Non-Small-Cell LungCutaneous MelanomaCarcinoma, Renal Cell+9 more
Novartis Pharmaceuticals 126
Testing effectiveness (Phase 2)Ended earlyNCT03637803
What this trial is testing

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Who this might be right for
OncologySolid TumorNon Small Cell Lung Cancer+3 more
4D pharma plc 63
Testing effectiveness (Phase 2)Ended earlyNCT05846646
What this trial is testing

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

Who this might be right for
Oligometastatic Disease
ImmuneSensor Therapeutics Inc. 6
Early research (Phase 1)Study completedNCT00923520
What this trial is testing

A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies

Who this might be right for
Renal Cell CarcinomaBreast CancerColon Cancer+2 more
National Cancer Institute (NCI) 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT05831891
What this trial is testing

Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma

Who this might be right for
Non-clear Cell Renal Cell Carcinoma
RenJi Hospital 40
Large-scale testing (Phase 3)Study completedNCT03849118
What this trial is testing

89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study

Who this might be right for
Clear Cell Renal Cell Carcinoma
Telix Pharmaceuticals (Innovations) Pty Limited 300
Early research (Phase 1)Temporarily pausedNCT05958199
What this trial is testing

NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

Who this might be right for
Metastatic Malignant Neoplasm
NextPoint Therapeutics, Inc. 131
Early research (Phase 1)Looking for participantsNCT07517198
What this trial is testing

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

Who this might be right for
Solid TumorSmall Cell Lung Cancer (SCLC)High Grade Neuroendocrine Cancer+9 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. 40
Testing effectiveness (Phase 2)Looking for participantsNCT06380816
What this trial is testing

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

Who this might be right for
Advanced Solid TumoursSquamous Cell Carcinoma of Head and NeckCarcinoma, Non-Small-Cell Lung+8 more
Cancer Research UK 167
Early research (Phase 1)Study completedNCT05788484
What this trial is testing

CDX-585 in Patients With Advanced Malignancies

Who this might be right for
Non-small Cell Lung CancerGastric CancerHead and Neck Cancer+11 more
Celldex Therapeutics 20
Early research (Phase 1)Looking for participantsNCT06242470
What this trial is testing

MGC026 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorAdvanced CancerMetastatic Cancer+19 more
MacroGenics 250
Testing effectiveness (Phase 2)Study completedNCT03241173
What this trial is testing

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

Who this might be right for
Advanced Malignancies
Incyte Biosciences International Sàrl 52
Testing effectiveness (Phase 2)Active Not RecruitingNCT02568267
What this trial is testing

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Who this might be right for
Breast CancerCholangiocarcinomaColorectal Cancer+13 more
Hoffmann-La Roche 534
Next Page